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Abstract: The promising results of crizotinib in molecularly se-
lected patients with advanced non-small cell lung cancer (NSCLC)
whose tumor cells had a novel fusion protein involving anaplastic
lymphoma kinase presented at the 2010 American Society of Clin-
ical Oncology reinforce once again the importance of understanding
molecular heterogeneity of lung cancer and careful patient selection.
Several other important issues were the subject of presentations
related to lung cancer at the recently concluded American Society of
Clinical Oncology annual meeting. The articles covered a wide
variety of topics including optimal staging techniques to detect
mediastinal nodal involvement, the role of platinum-based doublet
chemotherapy in the management of elderly patients with advanced
NSCLC, use of maintenance therapy with gemcitabine, and the
impact of early introduction of organized palliative care in improv-
ing the quality of life of patients with advanced NSCLC. This report
provides a brief overview of the presentations related to lung cancer
that are relevant to clinical practice and future research.
KeyWords: Crizotinib, Palliative care, Maintenance chemotherapy,
Locally advanced non-small cell lung cancer, Superior sulcus
tumors.
(J Thorac Oncol. 2011;6: 227–232)
The fact that we have made progress in the treatment ofnon-small cell lung cancer (NSCLC) over the past decade
is no longer a matter of dispute. The recognition that a subset
of patients with activating mutations in the epidermal growth
factor receptor tyrosine kinase (EGFR TK) responds dramat-
ically to the EGFR TK inhibitors is one example. Several
articles related to lung cancer, some more promising than
others, were presented at the 46th Annual meeting of the
American Society of Clinical Oncology (ASCO). These arti-
cles covered a wide variety of topics that are relevant to
early-stage, locally advanced, and metastatic NSCLC, though
as one would expect the major focus was on patients with
advanced NSCLC. Quite disappointingly, but not surpris-
ingly, no significant progress was reported in the treatment of
small cell lung cancer this year. In this overview, we will
summarize some key presentations that would be of interest
to the clinicians caring for patients with lung cancer.
EARLY-STAGE NSCLC
It is critical to appropriately stage patients with resect-
able NSCLC to optimize therapy and avoid needless thora-
cotomy in patients with locally advanced or metastatic
NSCLC. The optimal method of staging the mediastinal
lymph nodes (LNs) in patients who have potentially resect-
able NSCLC continues to evolve. Tournoy et al.1investigated
the current standard surgical staging (cervical mediastinos-
copy, Chamberlain procedure, or video-assisted surgery—
arm A) compared with the combination of endosonography
(endoscopic ultrasound or endoscopic bronchial ultrasound
followed by surgical staging—arm B). Patients were required
to have enlarged mediastinal or enlarged hilar LNs, central
tumors, or increased uptake on fluorodeoxyglucose positron
emission tomography in a small mediastinal LN. Patients
who had mediastinal invasion, bulky mediastinal LNs, or
evidence of distant disease in fluorodeoxyglucose positron
emission tomography were excluded. The primary endpoint
was the sensitivity of both approaches for malignant involve-
ment at the N2 or N3 nodal stations, and secondary endpoints
were to compare the rate of complications and futile thora-
cotomy (defined as pathologic N2 involvement, T4, meta-
static disease, small cell lung cancer or benign disease, death
within 30 days, and exploratory thoracotomy). Of the 357
patients screened, 241 were randomized to arm A (n  118)
or arm B (n  123). Use of endoscopic staging resulted in a
statistically significant higher sensitivity for N2 or N3 nodal
involvement (94% versus 80%, p  0.04) and a lower rate of
futile thoracotomy (7% versus 18%, p  0.009), with no
significant differences in the rate of complications (5% versus
6%, p 0.78). The addition of endoscopic evaluation seemed
to improve the accuracy of mediastinal nodal staging of
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patients with resectable NSCLC and is already being incor-
porated in many institutions as a standard preoperative stag-
ing technique.
The National Cancer Institute of Canada initiated a
double-blinded placebo controlled trial of gefitinib in patients
with resected stage IB to stage IIIA NSCLC (BR 19) several
years ago when phase II studies reported promising results
with gefitinib in patients with advanced NSCLC.2 The BR 19
trial was discontinued, and the patients were asked to termi-
nate study therapy after the disappointing results from phase
III studies with gefitinib.3,4 The results from this aborted trial
were presented at this year’s ASCO meeting. As one would
expect, the median duration of study treatment was less than
5 months. Treatment with gefitinib compared with placebo
did not result in an improvement in overall survival (OS)
(hazard ratio [HR]  1.23; 95% confidence interval [CI]:
0.94–1.64; p  0.136) or disease-free survival (HR  1.22;
95% CI: 0.93–1.61; p  0.152). Of the 357 tumors analyzed,
281 had wild-type EGFR TK and 76 had an activating
mutations in the EGFR TK domain. In the placebo arm (n 
185), the presence of an activating EGFR TK mutation
compared with EGFR wild type was not prognostic for OS
(HR 1.06, 95% CI: 0.62–1.83; p 0.830). Among patients
with an EGFR TK mutation treatment with gefitinib com-
pared with placebo did not result in improved survival (HR
1.58; 95% CI: 0.83–3.00; p  0.160). This observation is in
contrast to advanced NSCLC where EGFR TK mutations
are associated with a better prognosis and predictive of
benefit of EGFR TK inhibitor. The small numbers of
patients included in the study with EGFR TK mutation and
the very brief duration of exposure to gefitinib are serious
limitations. The impact of EGFR TK inhibitors in patients
with resected NSCLC whose tumors have mutations in the
EGFR TK domain needs to be studied in a well-thought-
out prospective study.
Patients who survive with lung cancer are at risk for
developing a new primary lung cancer. Based on some
earlier observations that selenium has a potential to de-
crease the incidence of lung cancer, a large prospective
double-blinded randomized study comparing selenium
with placebo in 1561 patients with resected stage I NSCLC
was conducted by the Eastern Cooperative Oncology Group
in partnership with other cooperative groups in the United
States.5,6 Quite disappointingly, the rate of lung cancers was
lower among patients assigned to the placebo arm compared
with the selenium arm, 1.36 and 1.91 per 100 person years,
respectively (two-sided p value  0.150). The overall rate of
second malignancies was numerically lower in the placebo
arm as well. Unfortunately, chemoprevention of lung cancer
continues to be an elusive dream.
LOCALLY ADVANCED NSCLC
Chemoradiation followed by surgical resection is con-
sidered standard of therapy in patients with resectable supe-
rior sulcus tumors. Results from a long term (7 years) fol-
low-up analysis of Japan Clinical Oncology Group Trial 9806
were presented at this meeting. In this prospective trial,
patients with superior sulcus tumors were treated with of
preoperative concurrent radiation (45 Gray) with chemother-
apy (mitomycin C, vindesine, and cisplatin) followed by
surgical resection or boost radiotherapy up to 66.6 Gray.7
Seventy-six patients were enrolled, of which 75 were fully
assessable. Fifty-seven patients underwent thoracotomy, of
which 56 patients had surgical resection with complete re-
section in 51 patients. At the time of the 7-year follow-up, 41
patients had died: 76% due to NSCLC and 7% to treatment-
related adverse events. The median OS was 7.61 years, and
median progression-free survival (PFS) was 2.31 years, and
7-year PFS was 44%. Twelve patients had achieved a patho-
logic complete response, and their 7-year OS was 92%. This
follow-up analysis confirmed the safety and efficacy of the
neoadjuvant approach in this population.
FIRST-LINE THERAPY IN METASTATIC NSCLC
Lung cancer is a disease of the elderly, and the optimal
management of elderly patients with advanced NSCLC is
increasingly becoming an important topic for research, par-
ticularly given the increasing life expectancy of the general
population. At the plenary session, results from a randomized
phase III study were presented comparing a double-agent
chemotherapy regimen of carboplatin (area under the curve
6) every 28 days and paclitaxel 90 mg/m2 on days 1, 8, and
15 every 28 days for four cycles (n  225) with a single-
agent therapy (gemcitabine 1150 mg/m2 or vinorelbine 30
mg/m2 on days 1 and 8 every 21 days) for five cycles (n 
226) in patients with metastatic NSCLC who were 70 to 89
years of age at the time of presentation.8 Patients at the time
of disease progression or unacceptable toxicity received er-
lotinib. There was a significant improvement in OS with the
doublet chemotherapy regimen compared with monotherapy
(median OS of 10.3 versus 6.2 months, respectively, and
1-year survival rate of 45.1% versus 26.9%, respectively, p
0.00004) with the accompanying improvement in PFS (me-
dian PFS 6.1 versus 3.0 months, respectively, p  106).
Predictably, this improvement in PFS and OS with the dou-
blet therapy came with a significantly higher rate of febrile
neutropenia (9.6% versus 2.9%), thrombocytopenia (6.3%
versus 1%), and sensory neuropathy (2.9% versus 0%) and a
higher rate of treatment-related death (6.62 versus 1.83%,
p  0.035), when compared with monotherapy. The results
from this study once again underscore the benefit of plati-
num-based doublet therapy in patients with advanced NSCLC
even in elderly patients.
The impact of early integration of palliative care with
the standard care was investigated in a randomized phase III
trial involving 107 evaluable patients with metastatic
NSCLC.9 Patients assigned to the early palliative care arm
met with a member of the palliative care team, which con-
sisted of a board-certified palliative care physician and ad-
vanced practice nurses, within 3 weeks of trial enrollment and
at least monthly until death. The primary outcome was
quality of life (QoL) as assessed using Functional Assessment
of Cancer Therapy-Lung (FACT-L), which assess physical,
functional, emotional, and social well being (higher scores
indicating better QoL), Lung Cancer Subscale (LCS), which
assess seven symptoms specific to lung cancer (higher scores
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indicate fewer symptoms), and the Trial Outcome Index,
which is the sum of the scores on the LCS and physical and
functional well being subscales of the FACT-L (higher scores
indicating better QoL). Secondary endpoints were the symp-
toms of anxiety and depression using the Hospital Anxiety
and Depression Scale (range: 0 [no distress] to 21 [maximum
distress]) and rate of aggressive end-of-life care, which is
defined as chemotherapy within 14 days before death, no
hospice care, or admission to hospice care 3 days before
death. The basic demographics and treatment regimens were
similar in both the arms. Patients in the standard oncology
and early integration of palliative care arm compared with the
standard oncology arm experienced a better QoL (Table 1),
lower rate of depressive symptoms (16% versus 38%, p 
0.01), lower rate of aggressive care at the end of life (33%
versus 54%, p  0.05), and improved median OS (11.6
versus 8.9 months, p  0.02). This trial supports the integra-
tion of palliative care support services in combination with
standard oncology care rather than the current model of
sequential use of standard oncology care and palliative care.
Three studies evaluated the addition of a novel agent
to a regimen of paclitaxel and carboplatin in the first-line
therapy for metastatic NSCLC. Unfortunately, none of the
trials met their primary endpoints. Jassem et al.10 per-
formed a randomized multicenter international phase III
study of carboplatin and paclitaxel with and without figi-
tumumab (CP-751,871), a monoclonal antibody targeting
insulin-like growth factor type 1 receptor, in patients with
advanced NSCLC with nonadenocarcinoma (AC) histol-
ogy. After 681 of the planned 820 patients were accrued, the
study was suspended because the investigational arm had
crossed a prespecified futility boundary. Serious adverse
events included hyperglycemia, asthenia, anorexia, fatigue,
pneumonia, and dehydration. OS showed a trend favoring the
paclitaxel/carboplatin arm. No clinical parameters demon-
strated any favorable subsets. A randomized multicenter
three-arm phase II trial investigated carboplatin and pacli-
taxel with one of two different doses of mapatumumab, a
TRAIL-R1 monoclonal antibody, in 111 patients. The inves-
tigational arms were well tolerated but did not show any
improvement in response rate or PFS compared with pacli-
taxel and carboplatin alone.11 A phase III trial of carboplatin
and paclitaxel with and without NOV-002, a formulation of
oxidized glutathione which helps to regulate protein function,
in 903 patients with advanced NSCLC revealed that the
addition of NOV-002 did not improve OS, PFS or response
nor did it increase toxicity.12
The role of erlotinib in the frontline therapy for NSCLC
continues to be a topic of active research. The Cancer and
Leukemia Group B performed a randomized phase II trial
comparing erlotinib alone or in combination with carboplatin
and paclitaxel in never or light former smokers with advanced
lung AC.13 Both arms had similar efficacy (response rate,
PFS, and OS), but single-agent erlotinib had a numerically
lower rate of toxicity than the combination arm. Patients with
mutant EGFR achieved longer PFS and improved OS with
erlotinib, alone and in combination with chemotherapy, when
compared with those with wild-type tumors. This study along
with the results from the Iressa Pan-Asia Study (IPASS)
study support the use of EGFR tyrosine kinase inhibitor
(TKI) monotherapy in the frontline therapy for patients with
advanced NSCLC whose tumors are known to have EGFR
TK mutation.14
Tarceva Or Placebo In Clinically Advanced Lung can-
cer (TOPICAL), a randomized phase III trial comparing
erlotinib with placebo in chemotherapy-naive patients with
advanced NSCLC and unsuitable for first-line chemotherapy
(Eastern Cooperative Oncology Group performance status
[PS] 2–3 or 0–1 with impaired renal function).15 Approxi-
mately 50% of the patients were more than 77 years of age.
Erlotinib did not improve OS but did result in a clinically
insignificant improvement in PFS (2.8 months versus 2.7
months, p  0.038) compared with placebo. In preplanned
subgroup analyses, erlotinib improved OS and PFS in female
patients, regardless of histology, EGFR mutation status,
smoking status, or performance status. Erlotinib may be
considered for women in first-line therapy with poor PS who
may not be eligible for cytotoxic therapy.
MAINTENANCE THERAPY IN METASTATIC
NSCLC
Use of pemetrexed or erlotinib in the maintenance
setting in patients with metastatic NSCLC who do not have
progressive disease after four cycles of platinum-based ther-
apy improves OS compared with placebo.16,17 At ASCO, this
year, several trials investigating different maintenance ther-
apy strategies were presented. A three-arm phase III trial
investigated the efficacy of maintenance therapy with gem-
citabine or erlotinib compared with observation after four
cycles of cisplatin and gemcitabine.18 The primary endpoint
was PFS by independent review. The trial was not designed
to compare the efficacy of erlotinib with gemcitabine, and
patients in all treatment arms were offered pemetrexed at the
TABLE 1. Quality of Life Analysis and Outcomes at 12 Wk9
Metric Range
Standard of Care
(N  47)
Early Palliative Care
(N  60) Difference p
FACT-L 0–136 91.5 98.0 6.5 (95%CI: 0.5–12.4) 0.03
LCS 0–28 19.3 21.0 1.7 (95% CI: 0.1–3.2) 0.04
TOI 0–84 53.0 59.0 6.0 (95%CI: 1.5–10.4) 0.009
FACT-L, Functional Assessment of Cancer Therapy-Lung; LCS, Lung Cancer Subscale; TOI, Trial Outcome Index; CI,
confidence interval.
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time of disease progression. The trial demonstrated an im-
provement in PFS with erlotinib or gemcitabine maintenance
therapy compared with observation. More follow-up is nec-
essary before determining the impact of this approach on OS
(Table 2). A second phase III trial compared gemcitabine
maintenance therapy to best supportive care (BSC) after
initial therapy with carboplatin and gemcitabine.19 The pri-
mary endpoint was OS. The trial did not reveal an improve-
ment in PFS or OS with maintenance gemcitabine, and the
median PFS and OS were numerically lower on the gemcit-
abine arm compared with the BSC arm (Table 2). The PFS
observed with continuation gemcitabine and BSC in the trials
by Perol et al. and Belani et al. is numerically different. It is
unclear whether differences in the radiologic assessment
schedule, patient populations, investigator versus indepen-
dent assessment, or a combination of factors contributed to
the different PFS observed in the two trials. Importantly,
these results are preliminary, and we await the full publica-
tion of both trials to better assess this issue. In the trial by
Belani et al, approximately 55 to 60% of patients had a PS of
2 at time of enrollment. A PS of 2 and male gender were
associated with statistically significant worse survival. It is
worth noting that so far, improved OS has only been observed
when the systemic therapy was switched to a different agent
than what was used in the induction doublet regimen (so
called “switch maintenance therapy”).
A phase trial III investigated the standard sequence of
therapy with cisplatin and gemcitabine followed by erlotinib
at time of disease progression compared with the investiga-
tional sequence of first-line erlotinib followed by cisplatin
and gemcitabine at the time of disease progression.20 The trial
was designed to assess whether the investigational sequence
was noninferior in terms of OS. After the first interim anal-
ysis, the independent data monitoring committee recom-
mended study termination as the boundary for inferiority of
the investigational arm had been crossed. The median PFS
was numerically lower on the investigational arm, and the OS
was statistically significant lower at the interim and updated
OS analyses (Table 3). This trial indicates that the first-line
therapy with erlotinib followed by chemotherapy should not
be pursued in an unselected patient population.
SALVAGE THERAPY
The results from a phase II study of crizotinib (PF-
02341066), an inhibitor of anaplastic lymphoma kinase
(ALK) and Met/Hepatocyte Growth Factor (Met/HGF) recep-
tor tyrosine kinases, in ALK-positive patients with NSCLC
was presented at the plenary session.21 Seventy-six patients
with heavily pretreated advanced NSCLC (median number of
prior treatments  3, range: 0–7) identified as possessing
ALK fusion oncogene by fluorescence in situ hybridization
(FISH) analysis were treated with crizotinib 250 mg twice a
day orally. Majority of the patients in this study were never
smokers (76%) and had AC histology (96%). Overall re-
sponse rate was 57% with disease control rate of 87% and one
confirmed complete response. The median duration of treat-
ment was 5.7 months. Median PFS had not been reached at
the time of presentation, and the PFS rate at 6 months was
72% (95% CI: 61–83). The treatment was well tolerated with
the most frequent side effects being gastrointestinal (grades 1
and 2 nausea, diarrhea, and vomiting). An unusual side effect
of grade 1 visual disturbance (changes in light/dark accom-
modation with no abnormalities on ophthalmologic examina-
tion) has been reported with this agent as well. There was
only one grade 4 toxicity (alanine aminotransferase eleva-
tion). Several phase III trials of crizotinib in patients with
advanced NSCLC are currently ongoing. The fact that there
has been such a dramatic progress from the laboratory to the
clinic in a matter of a few years since the discovery of this
novel translocation is certainly encouraging.
TABLE 2. Phase III Trials of Maintenance Therapy
First Author
No. of
Patients Chemotherapy
No. of Patients
Randomized Comparison Median PFS (mo) Median OS (mo)
Perol et al.18 834 Cisplatin  gemcitabine 464 Observation (N  155) 1.9 NR
Gemcitabine (N  154) 3.8, HR  0.55, p  0.0001 NR, HR  0.86, p  NSa
Erlotinib (N  155) 2.9, HR  0.82, p  0.002 NR, HR  0.91, p  NSb
Belani et al.19 519 Carboplatin  gemcitabine 255 BSC (N  127) 7.7 9.3
Gemcitabine (N  128) 7.4, HR 1.09, p  0.575 8.0, HR  0.97, p  0.838
a Hazard ratio represents comparison of gemcitabine to observations.
b Hazard ratio represents comparison of erlotinib to observation.
PFS, progression-free survival; OS, overall survival; NR, not reported; NS, not significant; HR, hazard ratio; BSC, best supportive care.
TABLE 3. Phase III Trial Cisplatin and Gemcitabine Followed by Erlotinib Compared with Erlotinib
Followed by Cisplatin and Gemcitabine20
First-Line Therapy Second-Line Therapy PFS (mo) OS (mo)
Cisplatin  gemcitabine (N  380) Erlotinib (N  211) 5.7 12.0
Erlotinib (N  380) Cisplatin and gemcitabine (N  186) 2.2 8.5, HR  1.36, p  0.002a
a Median and HR represent updated survival analysis with median follow-up of 12.9 mo.
PFS, progression-free survival; OS, overall survival; HR, hazard ratio.
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PREDICTIVE VALUE OF BIOMARKERS
Excision repair cross-complementing gene 1 (ERCC1)
belongs to a family of nucleotide excision repair genes that
facilitates the repair of DNA damage induced by several
natural noxious stimuli thereby preserving genomic integrity.
Platinum compounds are heavy metal complexes that form
adducts with and cross-links between DNA molecules and,
thus, effectively block DNA replication and transcription.
ERCC1 repairs adducts and cross-links, therefore, inducing
resistance to platinum-based chemotherapy. ERCC1 mRNA
levels are, therefore, inversely associated with response and
survival to patients treated with platinum-containing regi-
mens. This inverse association between response and survival
has been suggested in malignancies of the stomach,22 esoph-
agus, colorectum,23 lung,24 and breast.25
In NSCLC, ERCC1-tailored chemotherapy has been
shown to statistically significantly improve response rates in
a randomized phase III trial26 and suggested survival benefit
in a phase II trial.27 Nevertheless, these studies were done in
biopsy specimens and, in most instances, required a second
biopsy to obtain sufficient tissue to perform the ERCC1
analysis. Hoffmann et al.,28 in an effort to eliminate the need
for a second biopsy, examined whether ERCC1 expression
levels in specifically enriched circulating tumor cells (CTCs)
were associated with response to platinum-based chemother-
apy. Blood was drawn from 75 consecutively treated patients
with advanced NSCLC 1 hour before chemotherapy on days
1 and 22 of first-line chemotherapy. CTC were enriched from
peripheral venous blood using a specifically designed buoy-
ant density gradient centrifugation. ERCC1 mRNA expres-
sion was then measured using a quantitative real-time poly-
merase chain reaction method. ERCC1 levels were then
correlated with response measured using the RECIST criteria
in CT scans. The authors report that ERCC1 expression levels
in CTC were significantly correlated with response (p 
0.003) to platinum-based chemotherapy. Additionally, when
they used the receiver operating characteristic curve analysis,
the sensitivity and specificity of high-ERCC1 expression
(75th percentile) to distinguish disease control (response or
stable disease) from progressive disease was 75% and 81.3%,
respectively. The area under the curve was 0.78 (CI: 0.612–
0.901) with a significance level of p  0.04. These results
suggest that ERCC1 levels measured in CTC could be used to
tailor chemotherapy in patient with advanced NSCLC. If
larger confirmatory studies confirm these findings then the
expense and risk of a second biopsy will be eliminated.
In patients with NSCLC, recent randomized trials have
suggested improved response rates and survival for women
(versus men) and ACs (versus squamous cell carcinomas
[SCCAs]). Even though the explanations for these observa-
tions could be complex and multifactorial, the findings re-
ported by Gandara et al.29 suggest that such histology- and
gender-related associations may be partially explained by
differing expression levels of biomarkers that predict for
chemotherapy response such as ERCC1, ribonucleotide re-
ductase M subunit 1 (RRM1), or thymidylate synthase (TS).
ERCC1, RRM1, and TS predict response to platinum, gem-
citabine, and pemetrexed, respectively. Median gene expres-
sion levels were used to dichotomize high versus low levels
which for ERCC1 was 1.7, RRM1 was 0.97, and TS was
2.33. Specimens from 1802 individuals with NSCLC were
analyzed for one or more biomarkers. For each biomarker,
gene expression was found to be higher in SCCA compared
with AC (0.001; Mann-Whitney U test). There were no
associations found between gene expression levels and age or
stage. Gene expression levels were statistically significantly
higher in men versus women: ERCC1: 2.51 versus 2.22, p 
0.005; RRM1: 1.41 versus 1.24, p  0.004; TS: 3.23 versus
2.83, p less than 0.001. Nevertheless, SCCA was found to be
more frequent in men versus women (30% versus 19%, p 
0.001, Fisher’s exact test). When AC and SCCA were as-
sessed separately, statistical significance between gene ex-
pression and gender was lost (in SCCA: ERCC1 p  0.14;
RRM1 p  0.26; TS p  0.11). These findings suggest that
the improved response and survival seen in women (versus
men) may be partially explained by the fact that there is
higher frequency of SCCA in men. Nevertheless, the
authors were careful to point out that, although significant
histology-related associations for ERCC1, RRM1, and TS
were seen, marked heterogeneity exists in individual pa-
tient expression levels.
An interesting association between EGFR mutation
status and ERCC1 expression was also reported at this meet-
ing. The presence of EGFR mutation was associated with
low-ERCC1 expression (p  0.001). This relationship was
retained by when adjusted for histologic subtype. This finding
may explain the higher response rates to chemotherapy seen
in EGFR-mutated patients (47.3%) versus the EGFR wild-
type patients (23.5%) in the IPASS trial, which is a phase III
randomized trial that compared first-line treatment with ge-
fitinib versus carboplatin plus paclitaxel in never or light
smoking Asian patients with advanced NSCLC.14 Neverthe-
less, the molecular basis for this association remains unclear
and requires further investigation.
SUMMARY
The contrast between the very encouraging results seen
with crizotinib in molecularly selected patients and disap-
pointing results from some large phase III studies where
molecularly targeted agents were combined somewhat em-
pirically without careful patient selection should force the
oncology community to rethink the well worn out strategy of
developing molecularly targeting agents with narrow spec-
trum of activity in broad unselected groups of patients, either
alone or in combination with other agents. The pace of
progress will only accelerate when we understand the molec-
ular diversity of lung cancer in greater detail and only when
biomarkers are developed early before large-scale studies are
launched. Ongoing efforts to resequence large numbers of
malignant tumors including lung cancer and the development
strategy for crizotinib offer considerable hope that we will
continue to make progress in the treatment of lung cancer.
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